A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study'

Int J Surg. 2023 Oct 1;109(10):3209-3210. doi: 10.1097/JS9.0000000000000588.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Cross-Sectional Studies
  • Humans
  • Neoadjuvant Therapy*
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / surgery